[의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)

 1  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-1
 2  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-2
 3  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-3
 4  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-4
 5  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-5
 6  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-6
 7  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-7
 8  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-8
 9  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-9
 10  [의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)-10
※ 미리보기 이미지는 최대 20페이지까지만 지원합니다.
  • 분야
  • 등록일
  • 페이지/형식
  • 구매가격
  • 적립금
자료 다운로드  네이버 로그인
소개글
[의학과][종양내과] VTE(VENOUS THROMBOEMBOLISM)에 대한 자료입니다.
목차
1.Epidemiology
2.Natural History
3.Risk Factors
4.Challenges of diagnosis
5.PULMONARY EMBOLISM MANAGEMENT
6.PREVENTION
7.Reference
본문내용
Cancer patients with venous thrombosis at diagnosis have a worse prognosis.
- Distant metastasis: 44% versus 35.1%
- 1 year survival rate: 12% versus 36%

Cancer patients are more likely to have large, proximal, persistent, and recurrent venous thrombosis.


Clinical diagnosis alone lacks sensitivity and specificity for acute venous thrombosis.

Diagnostic imaging studies such as duplex ultrasound and lung scintigraphy may provide more false-positive and false-negative results in cancer patients.

Plasma markers of coagulation activation do not predict development of thrombosis but can assist in prognosis determination.



Cancer patients are more likely to manifest heparin resistance and warfarin failure and to have limited venous access to support therapeutic anticoagulant monitoring.

Tendencies toward thrombocytopenia, osteopenia, malnutrition, brain metastasis, hepatic metastasis, and bleeding all complicate thrombosis care in cancer patients.
참고문헌
Abeloff: Abeloff's Clinical Oncology, 4th ed.
: Chapter 46 – Diagnosis, Treatment, and Prevention of Cancer-Related Venous Thrombosis

Rodger L. Bick. Cancer-Associated Thrombosis. New England Journal of Medicine. 349;2 109-111page